GOClic Website

GOC Statements

GOC Statements are developed by GOC members and key opinion leaders and are approved by GOC’s Board of Directors.

Cervical Cancer

Sentinel Lymph Node (SLN) Mapping in Endometrial and Cervical Cancer (July 2017)

Identification du ganglion sentinelle dans le contexte du cancer de l’endomètre et du col de l’utérus (Juillet 2017)

Endometrial Cancer

Sentinel Lymph Node (SLN) Mapping in Endometrial and Cervical Cancer (July 2017)

Identification du ganglion sentinelle dans le contexte du cancer de l’endomètre et du col de l’utérus (Juillet 2017)

Ovarian Cancer

The Use of PARP Inhibitors in the Treatment of Recurrent High-Grade Ovarian Cancer (August 2017)

Emploi des inhibiteurs de PARP dans le traitement de la récidive du cancer de l’ovaire de haut grade (Août 2017)

UPDATED: No Woman Left Behind: Toward a pan-Canadian Strategy for Universal BRCA Testing in Ovarian Cancer (February 2017)

MIS À JOUR: Aucune femme oubliée : vers une stratégie pancanadienne de dépistage universel des mutations des gènes BRCA dans le contexte du cancer de l’ovaire (février 2017)

GOC Opinion Statement Regarding the UK Collaborative Trial Of Ovarian Cancer Screening (UKCTOCS) Results (January 2016)

Surgical Care

GOC Response to “The Approaches to High-Risk, Resource Intensive Cancer Surgical Care in Canada”, a report from the Canadian Partnership Against Cancer (CPAC) (November 2015)

HPV

GOC, SOGC, SCC, CFPC Joint Position Statement Regarding the Safety of Gardasil HPV Vaccine (February 2015)

GOC, SOGC, SCC, CFPC – Déclaration de principe commune: Innocuité du vaccin anti-VPH Gardasil (Février 2015)

 

To see more GOC Statements, click here.

Our Partners

The Society of Gynecologic Oncology of Canada welcomes and values industry partnerships.

GOC acknowledges the ongoing support of these dedicated partners for their commitment to gynecologic oncology in Canada. Thank you.

Become a Partner